No price history available.
Key financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥m | 2,688 | 3,203 | 2,838 | 3,430 | 2,872 | 2,419 | N/A | N/A |
| Operating profit | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ¥m | 157 | 72 | -774 | 104 | -301 | -241 | N/A | N/A |
| EPS reported | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Ligua Inc., founded in Osaka, Japan in 2004, operates as a consulting firm primarily offering management support services within the healthcare sector. The company's activities are structured across two main divisions: Orthopedic Clinic Solutions and Financial Services. In its Orthopedic Clinic Solutions segment, Ligua develops and provides specialized software, such as Ligoo POS & CRM for managing patient information in osteopathic clinics, and ReceONE, a system designed for calculating receipts for health insurance claim submissions. This division also supplies a variety of medical devices and supplies, including EMS-indepth-, an electrical muscle stimulation unit; the Thomson bed, a hydraulic-electric treatment table used for addressing pelvic and spinal misalignments; Inject Energy, a low-frequency treatment device aimed at alleviating deep tissue pain and improving muscle atrophy; and Dr.Supporter, a general medical device utilizing Integrated Functional Mineral Crystal technology to enhance blood circulation, promote fatigue recovery, ease muscle soreness and stiffness, relieve neuralgia and lower back pain, and support core strength. Furthermore, it delivers educational training consulting, including tailored programs and online client attraction strategies for orthopedic clinics, alongside medical expense billing agency services. Ligua's Financial Services arm is involved in insurance agency activities, financial instrument intermediation, and offers financial advisory services, including mediation for mergers and acquisitions, to a diverse range of businesses.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Ligua Inc., founded in Osaka, Japan in 2004, operates as a consulting firm primarily offering management support services within the healthcare sector. The company's activities are structured across two main divisions: Orthopedic Clinic Solutions and Financial Services. In its Orthopedic Clinic Solutions segment, Ligua develops and provides specialized software, such as Ligoo POS & CRM for managing patient information in osteopathic clinics, and ReceONE, a system designed for calculating receipts for health insurance claim submissions. This division also supplies a variety of medical devices and supplies, including EMS-indepth-, an electrical muscle stimulation unit; the Thomson bed, a hydraulic-electric treatment table used for addressing pelvic and spinal misalignments; Inject Energy, a low-frequency treatment device aimed at alleviating deep tissue pain and improving muscle atrophy; and Dr.Supporter, a general medical device utilizing Integrated Functional Mineral Crystal technology to enhance blood circulation, promote fatigue recovery, ease muscle soreness and stiffness, relieve neuralgia and lower back pain, and support core strength. Furthermore, it delivers educational training consulting, including tailored programs and online client attraction strategies for orthopedic clinics, alongside medical expense billing agency services. Ligua's Financial Services arm is involved in insurance agency activities, financial instrument intermediation, and offers financial advisory services, including mediation for mergers and acquisitions, to a diverse range of businesses.
